I have a friend kaylee right now dying from lung cancer...she was a 2 pk or more a day smoker for most of her life. she is a young 68 years old with no future. Yes no NO TOBACCO! Nancy Berry
----- Original Message ---- From: kaylee <[EMAIL PROTECTED]> To: MTWT <[EMAIL PROTECTED]> Sent: Wednesday, March 21, 2007 11:31:58 PM Subject: [cia-drugs] DON'T USE TOBACCO? Neither Do I I am aware that this has little to do with the drug war (except another possible prohibited substance), the prison situation, free speech (well, maybe free speech), world peace or constitutional law, but considering that lung cancer could easily affect you or someone you love, perhaps you can graciously overlook the fact that I'm off topic again and do something simple but wise for our future health. Kay Lee Petition for the Lung Cancer Aliance http://www.lungcanc eralliance. org/involved/ sign_the_ petition. php LUNG CANCER IS THE #1 CAUSE OF CANCER DEATH ANNUALLY AND HAS THE LEAST FUNDING!!!! Perhaps it's because, as part of the tobacco demonization effort, we have come to believe that people who use tobacco deserve cancer? Please show some compassion and common sense...not all people who die from lung cancer ever used tobacco... Just as not all people who use tobacco ever get lung cancer. This killer disease requires more funding, more research, and more effective treatments. Lung cancer continues to be the single biggest cancer killer. In 2006, an estimated 162,460 will die of lung cancer; more people than breast, prostate, colon, liver, melanoma, and kidney cancers combined. Few people are even aware that lung cancer kills three times as many men as prostate cancer, and nearly twice as many women as breast cancer. Prostate cancer has a 99 percent 5-year survival rate and breast cancer has an 88 percent 5-year survival rate. Over 50 percent of new lung cancer cases will be diagnosed at a very late stage—Stage IIIb or IV. Lung cancer has a 5-year survival rate of only 15 percent. That means that 85 percent of people who get lung cancer die within five years. THIS MUST BE CHANGED. Join the 14757 people who have already signed or downloaded the petition to make lung cancer a national public health priority. I join with the Lung Cancer Alliance to call on the President of the United States and members of Congress to increase funding to at least an additional 250 million dollars per year, for: medical research for early detection and curative treatment for lung cancer, and education and support for people diagnosed with lung cancer. We, the undersigned, call on the President of the United States and the Congress to make early detection, treatment, and chemoprevention of lung cancer a national public health priority. We also call for adequate new funding to increase the overall 5-year survival rate to at least 50 percent by 2015. SIGN THE PETITION and Please pass this on. http://www.lungcanc eralliance. org/involved/ sign_the_ petition. php <!-- #ygrp-mlmsg {font-size:13px;font-family:arial, helvetica, clean, sans-serif;} #ygrp-mlmsg table {font-size:inherit;font:100%;} #ygrp-mlmsg select, input, textarea {font:99% arial, helvetica, clean, sans-serif;} #ygrp-mlmsg pre, code {font:115% monospace;} #ygrp-mlmsg * {line-height:1.22em;} #ygrp-text{ font-family:Georgia; } #ygrp-text p{ margin:0 0 1em 0;} #ygrp-tpmsgs{ font-family:Arial; clear:both;} #ygrp-vitnav{ padding-top:10px;font-family:Verdana;font-size:77%;margin:0;} #ygrp-vitnav a{ padding:0 1px;} #ygrp-actbar{ clear:both;margin:25px 0;white-space:nowrap;color:#666;text-align:right;} #ygrp-actbar .left{ float:left;white-space:nowrap;} .bld{font-weight:bold;} #ygrp-grft{ font-family:Verdana;font-size:77%;padding:15px 0;} #ygrp-ft{ font-family:verdana;font-size:77%;border-top:1px solid #666; padding:5px 0; } #ygrp-mlmsg #logo{ padding-bottom:10px;} #ygrp-vital{ background-color:#e0ecee;margin-bottom:20px;padding:2px 0 8px 8px;} #ygrp-vital #vithd{ font-size:77%;font-family:Verdana;font-weight:bold;color:#333;text-transform:uppercase;} #ygrp-vital ul{ padding:0;margin:2px 0;} #ygrp-vital ul li{ list-style-type:none;clear:both;border:1px solid #e0ecee; } #ygrp-vital ul li .ct{ font-weight:bold;color:#ff7900;float:right;width:2em;text-align:right;padding-right:.5em;} #ygrp-vital ul li .cat{ font-weight:bold;} #ygrp-vital a { text-decoration:none;} #ygrp-vital a:hover{ text-decoration:underline;} #ygrp-sponsor #hd{ color:#999;font-size:77%;} #ygrp-sponsor #ov{ padding:6px 13px;background-color:#e0ecee;margin-bottom:20px;} #ygrp-sponsor #ov ul{ padding:0 0 0 8px;margin:0;} #ygrp-sponsor #ov li{ list-style-type:square;padding:6px 0;font-size:77%;} #ygrp-sponsor #ov li a{ text-decoration:none;font-size:130%;} #ygrp-sponsor #nc { background-color:#eee;margin-bottom:20px;padding:0 8px;} #ygrp-sponsor .ad{ padding:8px 0;} #ygrp-sponsor .ad #hd1{ font-family:Arial;font-weight:bold;color:#628c2a;font-size:100%;line-height:122%;} #ygrp-sponsor .ad a{ text-decoration:none;} #ygrp-sponsor .ad a:hover{ text-decoration:underline;} #ygrp-sponsor .ad p{ margin:0;} o {font-size:0;} .MsoNormal { margin:0 0 0 0;} #ygrp-text tt{ font-size:120%;} blockquote{margin:0 0 0 4px;} .replbq {margin:4;} -->